THE INSTITUTE FOR DISEASE MODELING
LEARN MORE ABOUT WHO WE ARE
LEARN MORE ABOUT WHAT WE DO
LEARN MORE ABOUT WHY
LEARN MORE ABOUT HOW WE WORK
LEARN MORE ABOUT WHERE WE WORK
The Institute for Disease Modeling is led by Robert Hart, director, and is part of the Bill & Melinda Gates Foundation’s Global Health Division.
IDM's goal is to support global efforts to eradicate infectious diseases and achieve permanent improvements in health by developing, using, and sharing computational modeling tools and promoting quantitative decision-making.
For opportunities to join IDM, please visit the Careers page for a list of current openings.
IDM is currently working on disease transmission dynamics for malaria, measles, polio, tuberculosis, HIV, pneumonia, typhoid, COVID-19, and many other diseases. Other areas of study include maternal, newborn, and child health conditions and interventions; health delivery strategies; health system access and effectiveness; family planning interventions; genomic surveillance; pathogen evolution; drug resistance; and other phenomena.
To achieve our goals, we develop deep expertise in the topics we work on and we develop customized high-fidelity and high-performance computer models. Our dedicated software team develops the tools researchers at IDM and our collaborating institutions need to answer policy questions, inform investments, and achieve our long-term research goals. These tools are flexible, fast, and robust. One example is our Epidemiological MODeling (EMOD) software platform, which enables large-scale agent-based models to run on supercomputers, both on premises and in the cloud. This software is open source and is made freely available to the global scientific community.
The control and eradication of infectious diseases is a pressing and complex problem that engages diverse contributors, from health workers on the ground to funding agencies that provide resources and support. Data modeling and statistical analysis make fundamental contributions that inform intervention strategies, resource allocation, and research into the causes and transmission of disease.
Disease modeling benefits the entire global health community by providing new insight into old problems, testing novel combinations of strategies, and enabling the collection of more valuable data in the field. The Institute for Disease Modeling (IDM) grew from a focus on malaria eradication to an institution working on multiple diseases, health care programs, and associated systems within the Bill & Melinda Gates Foundation. Our advancements in modeling provide powerful, state-of-the-art guidance and information for public health workers and institutions around the world.
IDM strongly values collaboration among people with varied backgrounds and skills. One thing that sets IDM apart from other modeling groups is the relationship between our research and software teams. Our researchers work with a dedicated software team that provides extensive professional experience in building, testing, and supporting our modeling tools. By following software best practices, this team can help build modeling tools that are easily extended to model a variety of different diseases and interventions.
We believe collaboration can magnify the impact of our work, so we work to build collaborations with partners worldwide, including universities, nongovernmental organizations, government ministries, and other research and public health institutions to achieve positive, important, and long long-lasting impacts on the health of people most in need.
IDM collaborates with selected universities, NGOs, government ministries, and other research and public health institutions throughout the world. Some of the recent research efforts are in the following areas:
• Polio eradication in Nigeria and Afghanistan
• Malaria transmission in Burkina Faso, Mali, Zambia, and Tanzania
• Tuberculosis in the gold mines of South Africa
A LOOK INTO THE RECENT EVENTS AT IDM
Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update
Most diagnostic tests for tuberculosis (TB) rely on sputum samples, which are difficult to obtain and have low sensitivity in immunocompromised patients, patients with disseminated TB, and children, delaying treatment initiation. The World Health Organization (WHO) calls for the development of a rapid, biomarker-based, non-sputum test capable of detecting all forms of TB at the point-of-care…
Sub-national levels and trends in contraceptive prevalence, unmet need, and demand for family planning in Nigeria with survey uncertainty
Background Ambitious global goals have been established to provide universal access to affordable modern contraceptive methods. To measure progress toward such goals in populous countries like Nigeria, it’s essential to characterize the current levels and trends of family planning (FP) indicators such as unmet need and modern contraceptive prevalence…
Cost-effectiveness of using environmental surveillance to target the roll-out typhoid conjugate vaccine
Since the prequalification of the Typhoid conjugate vaccine (TCV) by the WHO and subsequent position paper published in 2018, strategies for roll-out of the vaccine have been under discussion . The 2018 position paper recommends the introduction of TCV to be…